These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 16498555)

  • 1. [Brief coxib therapy lowers cardiovascular risk].
    Z Orthop Ihre Grenzgeb; 2006; 144(1):18. PubMed ID: 16498555
    [No Abstract]   [Full Text] [Related]  

  • 2. Bullous fixed drug eruption to etoricoxib--further evidence of intraepidermal CD8+ T cell involvement.
    Duarte AF; Correia O; Azevedo R; do Carmo Palmares M; Delgado L
    Eur J Dermatol; 2010; 20(2):236-8. PubMed ID: 20110201
    [No Abstract]   [Full Text] [Related]  

  • 3. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
    Krüger K
    MMW Fortschr Med; 2006 Nov; 148(48):12. PubMed ID: 17615761
    [No Abstract]   [Full Text] [Related]  

  • 4. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal.
    Sukel MP; van der Linden MW; Chen C; Erkens JA; Herings RM
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):9-19. PubMed ID: 17963198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 6. Stroke caused by small vessel occlusion in a patient taking etoricoxib and thalidomide.
    Wong EH; Leung TW; Wong KS
    J Neuroimaging; 2007 Jan; 17(1):87-8. PubMed ID: 17238877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effective pain management after hallux valgus correction].
    Mertens E
    Pflege Z; 2012 Jun; 65(6):339. PubMed ID: 22741330
    [No Abstract]   [Full Text] [Related]  

  • 8. [Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].
    Mühlbauer B; Timm J
    Med Klin (Munich); 2006 Aug; 101(8):673-5; author reply 678-9. PubMed ID: 17051669
    [No Abstract]   [Full Text] [Related]  

  • 9. [How many harmed by rofecoxib in Germany?].
    Scharnetzky E; Andersohn F; Schill W; Garbe E; Pigeot I
    Med Klin (Munich); 2006 Aug; 101(8):675-6; author reply 678-9. PubMed ID: 17051670
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse effects of etoricoxib: other considerations.
    Kim JA; Choi YS; Kim SH
    Mayo Clin Proc; 2005 Sep; 80(9):1233-4; author reply 1234. PubMed ID: 16178505
    [No Abstract]   [Full Text] [Related]  

  • 11. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C; Chan AT; Tramontano AC; Gazelle GS
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
    El Miedany Y; Youssef S; Ahmed I; El Gaafary M
    Ann Allergy Asthma Immunol; 2006 Jul; 97(1):105-9. PubMed ID: 16892790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balancing the cyclooxygenase portfolio.
    Armstrong PW
    CMAJ; 2006 May; 174(11):1581-2. PubMed ID: 16717266
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiac risks with COX-2 inhibitors.
    Ashworth AJ
    CMAJ; 2007 Feb; 176(4):489-92. PubMed ID: 17296963
    [No Abstract]   [Full Text] [Related]  

  • 15. Primary stabbing headache can be responsive to etoricoxib, a selective COX-2 inhibitor.
    O'Connor MB; Murphy E; Phelan MJ; Regan MJ
    Eur J Neurol; 2008 Jan; 15(1):e1. PubMed ID: 18171381
    [No Abstract]   [Full Text] [Related]  

  • 16. Cerebrovascular events after discontinuation of rofecoxib treatment.
    Andersohn F
    Cardiovasc Drugs Ther; 2007 Apr; 21(2):77-9. PubMed ID: 17404824
    [No Abstract]   [Full Text] [Related]  

  • 17. NSAID trials and the choice of comparators--questions of public health importance.
    Psaty BM; Weiss NS
    N Engl J Med; 2007 Jan; 356(4):328-30. PubMed ID: 17251528
    [No Abstract]   [Full Text] [Related]  

  • 18. [Coronary risks with NSAID and coxibs. The end of hysteria].
    Einecke D
    MMW Fortschr Med; 2006 Nov; 148(48):10, 12. PubMed ID: 17615760
    [No Abstract]   [Full Text] [Related]  

  • 19. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction - The coxib controversies.
    Rainsford KD
    Inflammopharmacology; 2005; 13(4):331-41. PubMed ID: 16354388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.